Edwards Preparing Prima Plus Stentless Heart Valve Postmarket Study
This article was originally published in The Gray Sheet
Edwards Lifesciences is preparing for a postmarket study to evaluate long-term effectiveness of the XenoLogiX anticalcification treatment used with its Prima Plus stentless porcine tissue heart valve following FDA approval of the valve Feb. 27.
You may also be interested in...
MEDTRONIC PRICING FREESTYLE VALVE AT PREMIUM TO ST. JUDE's TORONTO SPV, indicating a belief that the "advanced tissue technology" gives Medtronic an edge over its only competitor in the U.S. stentless porcine heart valve market. Premarket approval applications for the Medtronic and St. Jude stentless porcine heart valves cleared FDA on Nov. 25 and Nov. 24, respectively.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.